Virbac SA (VIRP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Virbac SA (VIRP) has a cash flow conversion efficiency ratio of 0.023x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€24.89 Million ≈ $29.09 Million USD) by net assets (€1.07 Billion ≈ $1.25 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Virbac SA - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Virbac SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Virbac SA balance sheet liabilities for a breakdown of total debt and financial obligations.
Virbac SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Virbac SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AIR CHINA LTD H ADR/20
F:AD2B
|
N/A |
|
Chengdu Xingrong Investment Co Ltd
SHE:000598
|
0.070x |
|
Standex International Corporation
NYSE:SXI
|
0.028x |
|
Genscript Biotech Corporation
F:G51
|
-0.021x |
|
Tikehau Capital
PA:TKO
|
0.074x |
|
Twist Bioscience Corp
NASDAQ:TWST
|
-0.054x |
|
Upstart Holdings Inc
NASDAQ:UPST
|
0.136x |
|
OPENLANE, Inc.
NYSE:OPLN
|
0.035x |
Annual Cash Flow Conversion Efficiency for Virbac SA (2002–2024)
The table below shows the annual cash flow conversion efficiency of Virbac SA from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see VIRP market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €1.04 Billion ≈ $1.22 Billion |
€204.22 Million ≈ $238.76 Million |
0.196x | +49.71% |
| 2023-12-31 | €909.92 Million ≈ $1.06 Billion |
€118.96 Million ≈ $139.07 Million |
0.131x | +10.81% |
| 2022-12-31 | €838.98 Million ≈ $980.86 Million |
€98.98 Million ≈ $115.72 Million |
0.118x | -34.14% |
| 2021-12-31 | €725.19 Million ≈ $847.82 Million |
€129.90 Million ≈ $151.87 Million |
0.179x | -1.30% |
| 2020-12-31 | €655.22 Million ≈ $766.02 Million |
€118.92 Million ≈ $139.03 Million |
0.181x | -23.89% |
| 2019-12-31 | €551.88 Million ≈ $645.20 Million |
€131.61 Million ≈ $153.86 Million |
0.238x | +41.41% |
| 2018-12-31 | €495.87 Million ≈ $579.73 Million |
€83.62 Million ≈ $97.76 Million |
0.169x | -25.10% |
| 2017-12-31 | €478.82 Million ≈ $559.79 Million |
€107.81 Million ≈ $126.04 Million |
0.225x | -17.69% |
| 2016-12-31 | €520.79 Million ≈ $608.85 Million |
€142.45 Million ≈ $166.54 Million |
0.274x | +185.41% |
| 2015-12-31 | €482.29 Million ≈ $563.85 Million |
€46.22 Million ≈ $54.04 Million |
0.096x | -39.55% |
| 2014-12-31 | €482.19 Million ≈ $563.73 Million |
€76.45 Million ≈ $89.37 Million |
0.159x | -10.78% |
| 2013-12-31 | €414.37 Million ≈ $484.45 Million |
€73.63 Million ≈ $86.08 Million |
0.178x | -27.04% |
| 2012-12-31 | €398.42 Million ≈ $465.79 Million |
€97.03 Million ≈ $113.44 Million |
0.244x | +23.73% |
| 2011-12-31 | €313.87 Million ≈ $366.94 Million |
€61.78 Million ≈ $72.23 Million |
0.197x | -29.06% |
| 2010-12-31 | €302.35 Million ≈ $353.48 Million |
€83.90 Million ≈ $98.08 Million |
0.277x | +1.18% |
| 2009-12-31 | €236.20 Million ≈ $276.14 Million |
€64.78 Million ≈ $75.73 Million |
0.274x | +30.39% |
| 2008-12-31 | €201.01 Million ≈ $235.01 Million |
€42.28 Million ≈ $49.43 Million |
0.210x | -23.17% |
| 2007-12-31 | €184.28 Million ≈ $215.45 Million |
€50.45 Million ≈ $58.98 Million |
0.274x | -7.49% |
| 2006-12-31 | €164.93 Million ≈ $192.82 Million |
€48.81 Million ≈ $57.06 Million |
0.296x | +32.55% |
| 2005-12-31 | €160.19 Million ≈ $187.28 Million |
€35.76 Million ≈ $41.81 Million |
0.223x | -29.10% |
| 2004-12-31 | €131.17 Million ≈ $153.35 Million |
€41.30 Million ≈ $48.29 Million |
0.315x | +52.97% |
| 2003-12-31 | €129.09 Million ≈ $150.91 Million |
€26.57 Million ≈ $31.07 Million |
0.206x | -11.79% |
| 2002-12-31 | €132.52 Million ≈ $154.93 Million |
€30.92 Million ≈ $36.15 Million |
0.233x | -- |
About Virbac SA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. I… Read more